Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?-Reference-Cited by-同舟云学术

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Published:2018-10 Issue:8 Volume:119 Page:937-939
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Watson Sarah,Menis Jessica,Baldini Capucine,Martin-Romano Patricia,Michot Jean-Marie,Hollebecque Antoine,Armand Jean-Pierre,Massard Christophe,Soria Jean-Charles,Postel-Vinay Sophie,Paoletti Xavier

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0245-0.pdf

Reference12 articles.

1. Sleijfer, S. & Wagner, A. J. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. J. Clin. Oncol. 30, 896–898 (2012).

2. Ratain, M. J. & Eckhardt, S. G. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J. Clin. Oncol. 22, 4442–4445 (2004).

3. Dhani, N., Tu, D., Sargent, D. J., Seymour, L. & Moore, M. J. Alternate endpoints for screening phase II studies. Clin. Cancer Res. 15, 1873–1882 (2009).

4. Cirkel, G. A. et al. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies. Ann. Oncol. 27, 1638–1643 (2016).

5. Radovich, M. et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget 7, 56491–56500 (2016).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives;Gynecologic Oncology Reports;2022-08

2. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications;ESMO Open;2021-04

3. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis;Cancers;2021-03-08

4. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade;International Journal of Radiation Oncology*Biology*Physics;2020-09

5. Des études mono-bras aux études de comparaison externe. Considérations méthodologiques et recommandations;Therapies;2020-01